Cerebral glutamate and EAA levels in an acute phase of SAH are already high in patients with neurologically poor status and cerebral edema; elevated glutamate levels with depletion of the eNOS substrates were reported to be an independent predictor of poor outcomes in a clinical setting [112,116]. This evidence concerns the gene NOS3 and brain edema.